Close
Close
Treatment Database
autologous genetically engineered T cells that express a single-domain antibody that recognizes human mesothelin fused to the cluster of differentiation 3e subunit of the T cell receptor
Trade Name not avaiable
Orphan Indication Mesothelioma
USA Market Approval
USA Designation Date 01-02-2019
Sponsor TCR2 Therapeutics, Inc.
100 Binney Street, Suite 710
Cambridge, Massachusetts, 02142
More about Malignant pleural mesothelioma
Free Newsletter
Related Videos